Chelmsford/London – Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, in combination with selective estrogen receptor modulators (SERMs) such as tamoxifen, could slow or even stop the progression of Peyronie's disease if administered early. This was reported by a British research group in the Journal of Sexual Medicine (2026;...
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Chelmsford/London – Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, in combination with selective estrogen receptor modulators (SERMs) such as tamoxifen, could slow or even stop the progression of Peyronie's disease if administered early. This was reported by a British research group in the Journal of Sexual Medicine (2026;...